American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

GEOMETRY Mono-1: Capmatinib in MET Exon 14–Mutated Advanced NSCLC

ASCO 2021 – Lung Cancer

Deep and durable responses with a manageable toxicity profile were achieved with capmatinib treatment in patients with MET exon 14–mutated advanced profile non–small-cell lung cancer (NSCLC) regardless of line of therapy. Read More ›

Videos Year in Review

Key Abstracts from ASCO 2021 in NSCLC

By Mark A. Socinski, MD

AACR & ASCO 2021 – Midyear Review

Dr Mark Socinski reviews a broad variety of studies, including the evolving role of EGFR inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC. Read More ›

ASCO 2020 Lung Cancer Highlights

ASCO 2020 – Lung Cancer

Although the American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually because of the COVID-19 pandemic, hundreds of abstracts, posters, and presentations were still made available to inform clinicians on the latest developments in the treatment of lung cancer. This publication features some of the key highlights from the meeting, which can be used to improve the management and care of patients with the disease.

Clinical Activity of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion–Positive NSCLC

ASCO 2020 – Wrap Up

Results from the ARROW study showed that pralsetinib has rapid, potent, and durable clinical activity in patients with advanced RET fusion–positive non–small-cell lung cancer, regardless of RET fusion genotype or prior therapies. Read More ›

Adjuvant Concurrent Chemoradiotherapy in Extrahepatic Cholangiocarcinoma

ASCO 2020 – Cholangiocarcinoma

The use of adjuvant chemoradiotherapy was associated with improved overall survival compared with chemotherapy alone in patients with resected extrahepatic cholangiocarcinoma. Read More ›

Retrospective Analysis of Post Second-Line Chemotherapy Outcomes with Advanced or Metastatic CCA and FGFR2 Fusions

ASCO 2020 – Cholangiocarcinoma

In a phase 2 trial of patients with cholangiocarcinoma and FGFR2 fusions, infigratinib administered as third- and later-line chemotherapy treatment resulted in a meaningful progression-free survival and objective response rate benefit. Read More ›

FOENIX-CCA2: Phase 2, Open-Label, Multicenter Study of Futibatinib in Patients with iCCA Harboring FGFR2 Gene Fusions

ASCO 2020 – Cholangiocarcinoma

Preliminary data are reported for a phase 2, open-label multicenter study of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. Read More ›

Natural History of Fibroblast Growth Factor Receptor–Altered Cholangiocarcinoma

ASCO 2020 – Cholangiocarcinoma

The clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations are reported based on a retrospective chart review. Read More ›

Phase 2 Study of mFOLFOX versus mFOLFIRI in Locally Advanced or Metastatic BTC Refractory to First-Line Chemotherapy

ASCO 2020 – Cholangiocarcinoma

This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer. Read More ›

TreeTopp: Randomized Phase 2 Study of Varlitinib plus Capecitabine versus Placebo in Second-Line Advanced or Metastatic BTC

ASCO 2020 – Cholangiocarcinoma

Varlitinib plus capecitabine was compared with capecitabine plus placebo as second-line treatment in patients with advanced or metastatic biliary tract cancer. Read More ›

Page 9 of 31

6
7
8
9
10
11
12

Conference Coverage Proudly Presented by

American Health & Drug Benefits

Journal of Hematology Oncology Pharmacy

Journal of Oncology Navigation & Survivorship

Oncology Practice Management

Personalized Medicine in Oncology

The Oncology Nurse–APN/PA

The Oncology Pharmacist

Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications